Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity

References

• Ausio J. MeCP2 and the enigmatic organization of brain chromatin. Implications for depression and cocaine addiction. Clin Epigenetics. 2016;8:58. doi:10.1186/s13148-016-0214-5. PMID:27213019
   PubMed Web of Science ®Google Scholar
• Gabel HW, Kinde B, Stroud H, Gilbert CS, Harmin DA, Kastan NR, Hemberg M, Ebert DH, Greenberg ME. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. Nature. 2015;522:89-93. doi:10.1038/nature14319. PMID:25762136
   PubMed Web of Science ®Google Scholar
• Thambirajah AA, Ng MK, Frehlick LJ, Li A, Serpa JJ, Petrotchenko EV, Silva-Moreno B, Missiaen KK, Borchers CH, Adam Hall J, et al. MeCP2 binds to nucleosome free (linker DNA) regions and to H3K9/H3K27 methylated nucleosomes in the brain. Nucleic Acids Res. 2011;40:2884-97. doi:10.1093/nar/gkr1066. PMID:22144686
   PubMed Web of Science ®Google Scholar
• Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224-9. doi:10.1126/science.1153252. PMID:18511691
   PubMed Web of Science ®Google Scholar
• Yasui DH, Peddada S, Bieda MC, Vallero RO, Hogart A, Nagarajan RP, Thatcher KN, Farnham PJ, Lasalle JM. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci U S A. 2007;104:19416-21. doi:10.1073/pnas.0707442104. PMID:18042715
   PubMed Web of Science ®Google Scholar
• Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, Andrews R, Bird AP. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell. 2010;37:457-68. doi:10.1016/j.molcel.2010.01.030. PMID:20188665
   PubMed Web of Science ®Google Scholar
• Ausió J, de Paz A, Esteller M. MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol Med. 2014;20:487-98. doi:10.1016/j.molmed.2014.03.004. PMID:24766768
   PubMed Web of Science ®Google Scholar
• Zoghbi HY. Rett Syndrome and the ongoing legacy of close clinical observation. Cell. 2016;167:293-7. doi:10.1016/j.cell.2016.09.039. PMID:27716498
   PubMed Web of Science ®Google Scholar
• Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. Embo J. 2003;22:6335-45. doi:10.1093/emboj/cdg604. PMID:14633992
   PubMed Web of Science ®Google Scholar
• Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 2006;66:8342-6. doi:10.1158/0008-5472.CAN-06-1932. PMID:16951140
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8(9). doi:10.1101/cshperspect.a019505. PMID:27194046
   PubMed Web of Science ®Google Scholar
• Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl. 2000;Suppl 35:78-83. doi:10.1002/1097-4644(2000)79:35+<78::AID-JCB1129>3.0.CO;2-J. PMID:11389535
   PubMedGoogle Scholar
• Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Lim E, Culhane AC, Barry WT, Schumacher SE, Beroukhim R, et al. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy. Cancer Discov. 2015;6(1):45-58. PMID:26546296
   PubMed Web of Science ®Google Scholar
• Garcia Ramirez M, Rocchini C, Ausió J. Modulation of chromatin folding by histone acetylation. J Biol Chem. 1995;270:17923-8. doi:10.1074/jbc.270.30.17923. PMID:7629098
   PubMed Web of Science ®Google Scholar
• Wakamori M, Fujii Y, Suka N, Shirouzu M, Sakamoto K, Umehara T, Yokoyama S. Intra- and inter-nucleosomal interactions of the histone H4 tail revealed with a human nucleosome core particle with genetically-incorporated H4 tetra-acetylation. Sci Rep. 2015;5:17204. doi:10.1038/srep17204. PMID:26607036
   PubMed Web of Science ®Google Scholar
• Wang X, He C, Moore SC, Ausió J. Effects of histone acetylation on the solubility and folding of the chromatin fiber. J Biol Chem. 2001;276:12764-8. doi:10.1074/jbc.M100501200. PMID:11279082
   PubMed Web of Science ®Google Scholar
• Calestagne-Morelli A, Ausio J. Long-range histone acetylation: biological significance, structural implications, and mechanisms. Biochem Cell Biol. 2006;84:518-27. doi:10.1139/o06-067. PMID:16936824
   PubMed Web of Science ®Google Scholar
• Ausió J, Abbott DW. The role of histone variability in chromatin stability and folding. Amsterdam, The Netherlands: Elsevier; 2004.p. 241-90.
   Google Scholar
• Zago V, Pinar-CabezaDeVaca C, Vincent JB, Ausio J. Histone variants and composition in the developing brain: should MeCP2 care? Curr Top Med Chem. 2016;17(7):829–42. PMID:27086783
   Web of Science ®Google Scholar
• Mitrousis N, Tropepe V, Hermanson O. Post-Translational Modifications of Histones in Vertebrate Neurogenesis. Front Neurosci. 2015;9:483. doi:10.3389/fnins.2015.00483. PMID:26733796
   PubMed Web of Science ®Google Scholar
• Bonnaud EM, Suberbielle E, Malnou CE. Histone acetylation in neuronal (dys)function. Biomol Concepts. 2016;7:103-16. doi:10.1515/bmc-2016-0002. PMID:27101554
   PubMedGoogle Scholar
• Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001;48 Suppl 1:S20-6. doi:10.1007/s002800100300. PMID:11587361
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287-99. doi:10.1038/nrd772. PMID:12120280
   PubMed Web of Science ®Google Scholar
• La Thangue NB. Histone deacetylase inhibitors and cancer therapy. J Chemother. 2004;16 Suppl 4:64-7. doi:10.1179/joc.2004.16.Supplement-1.64. PMID:15688613
   PubMedGoogle Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5:981-9. doi:10.1158/1541-7786.MCR-07-0324. PMID:17951399
   PubMed Web of Science ®Google Scholar
• Noureen N, Rashid H, Kalsoom S. Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol. 2010;66:625-33. doi:10.1007/s00280-010-1324-y. PMID:20401613
   PubMed Web of Science ®Google Scholar
• Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90:85-94. doi:10.1038/icb.2011.100. PMID:22124371
   PubMed Web of Science ®Google Scholar
• Delcuve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets. 2013;17:29-41. doi:10.1517/14728222.2013.729042. PMID:23062071
   PubMed Web of Science ®Google Scholar
• Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:161-9.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han Y, Jiang Q, Wang C, Chen X, Li X, Xu F, Jiang Y, Wang Q, Xu W. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev. 2015;35:63-84. doi:10.1002/med.21320. PMID:24782318
   PubMed Web of Science ®Google Scholar
• Turtoi A, Peixoto P, Castronovo V, Bellahcene A. Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives. Crit Rev Oncog. 2015;20:119-37. doi:10.1615/CritRevOncog.2014012423. PMID:25746107
   PubMedGoogle Scholar
• Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6. doi:10.1101/cshperspect.a026831. PMID:27599530
   PubMed Web of Science ®Google Scholar
• Damaskos C, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A, Davakis S, et al. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res. 2017;37:35-46. doi:10.21873/anticanres.11286. PMID:28011471
   PubMed Web of Science ®Google Scholar
• Ganai SA, Ramadoss M, Mahadevan V. Histone Deacetylase (HDAC) Inhibitors – emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration. Curr Neuropharmacol. 2016;14:55-71. doi:10.2174/1570159X13666151021111609. PMID:26487502
   PubMed Web of Science ®Google Scholar
• Penney J, Tsai LH. Histone deacetylases in memory and cognition. Sci Signal. 2014;7:re12. doi:10.1126/scisignal.aaa0069. PMID:25492968
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673-91. doi:10.1038/nrd4360. PMID:25131830
   PubMed Web of Science ®Google Scholar
• Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci. 2010;31:605-17. doi:10.1016/j.tips.2010.09.003. PMID:20980063
   PubMed Web of Science ®Google Scholar
• Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32:591-601. doi:10.1016/j.tins.2009.06.002. PMID:19775759
   PubMed Web of Science ®Google Scholar
• Echaniz-Laguna A, Bousiges O, Loeffler JP, Boutillier AL. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr Med Chem. 2008;15:1263-73. doi:10.2174/092986708784534974. PMID:18537606
   PubMed Web of Science ®Google Scholar
• Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord. 2005;4:41-50. doi:10.2174/1568007053005091. PMID:15723612
   PubMedGoogle Scholar
• Bojang P, Jr, Ramos KS. The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev. 2014;40:153-69. doi:10.1016/j.ctrv.2013.05.009. PMID:23831234
   PubMed Web of Science ®Google Scholar
• Halsall JA, Turner BM. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success. Bioessays. 2016;38(11):1102-1110. doi:10.1002/bies.201600070. PMID:27717012
   PubMed Web of Science ®Google Scholar
• Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci. 2007;10:1513-4. doi:10.1038/nn2010. PMID:17994015
   PubMed Web of Science ®Google Scholar
• Hollander JA, Im HI, Amelio AL, Kocerha J, Bali P, Lu Q, Willoughby D, Wahlestedt C, Conkright MD, Kenny PJ. Striatal microRNA controls cocaine intake through CREB signalling. Nature. 2010;466:197-202. doi:10.1038/nature09202. PMID:20613834
   PubMed Web of Science ®Google Scholar
• Im HI, Hollander JA, Bali P, Kenny PJ. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci. 2010;13:1120-7. doi:10.1038/nn.2615. PMID:20711185
   PubMed Web of Science ®Google Scholar
• Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56:422-37. doi:10.1016/j.neuron.2007.10.001. PMID:17988628
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Thambirajah AA, Ausio J. MeCP2 preferentially binds to methylated linker DNA in the absence of the terminal tail of histone H3 and independently of histone acetylation. FEBS Lett. 2008;582:1157-62. doi:10.1016/j.febslet.2008.03.005. PMID:18339321
   PubMed Web of Science ®Google Scholar
• Host L, Dietrich JB, Carouge D, Aunis D, Zwiller J. Cocaine self-administration alters the expression of chromatin-remodelling proteins; modulation by histone deacetylase inhibition. J Psychopharmacol. 2011;25:222-9. doi:10.1177/0269881109348173. PMID:19939859
   PubMed Web of Science ®Google Scholar
• Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M, Jacob ST. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol. 2002;22:8302-19. doi:10.1128/MCB.22.23.8302-8319.2002. PMID:12417732
   PubMed Web of Science ®Google Scholar
• Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 1997;88:471-81. doi:10.1016/S0092-8674(00)81887-5. PMID:9038338
   PubMed Web of Science ®Google Scholar
• Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386-9. doi:10.1038/30764. PMID:9620804
   PubMed Web of Science ®Google Scholar
• Eden S, Hashimshony T, Keshet I, Cedar H, Thorne AW. DNA methylation models histone acetylation. Nature. 1998;394:842. doi:10.1038/29680. PMID:9732866
   PubMed Web of Science ®Google Scholar
• Ballestar E, Esteller M. The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. Prog Mol Subcell Biol. 2005;38:169-81. doi:10.1007/3-540-27310-7_7. PMID:15881895
   PubMedGoogle Scholar
• Ballestar E, Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol. 2005;83:374-84. doi:10.1139/o05-035. PMID:15959563
   PubMed Web of Science ®Google Scholar
• Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, Karimi M, Ekstrom TJ, Szyf M. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol. 2007;73:1297-307. doi:10.1016/j.bcp.2006.12.032. PMID:17276411
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3:166-79. PMID:21416059
   PubMed Web of Science ®Google Scholar
• Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem. 2004;11:1629-43. doi:10.2174/0929867043365099. PMID:15180568
   PubMed Web of Science ®Google Scholar
• Mateos-Langerak J, Brink MC, Luijsterburg MS, van der Kraan I, van Driel R, Verschure PJ. Pericentromeric heterochromatin domains are maintained without accumulation of HP1. Mol Biol Cell. 2007;18:1464-71. doi:10.1091/mbc.E06-01-0025. PMID:17314413
   PubMed Web of Science ®Google Scholar
• Guenatri M, Bailly D, Maison C, Almouzni G. Mouse centric and pericentric satellite repeats form distinct functional heterochromatin. J Cell Biol. 2004;166:493-505. doi:10.1083/jcb.200403109. PMID:15302854
   PubMed Web of Science ®Google Scholar
• Hu K, Nan X, Bird A, Wang W. Testing for association between MeCP2 and the brahma-associated SWI/SNF chromatin-remodeling complex. Nat Genet. 2006;38:962-4; author reply 4–7. doi:10.1038/ng0906-962. PMID:16940996
   PubMed Web of Science ®Google Scholar
• Felisbino MB, Gatti MS, Mello ML. Changes in chromatin structure in NIH 3T3 cells induced by valproic acid and trichostatin A. J Cell Biochem. 2014;115:1937-47. PMID:24913611
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Dryhurst D, Rose KL, Shabanowitz J, Hunt DF, Ausio J. Acetylation of vertebrate H2A.Z and its effect on the structure of the nucleosome. Biochemistry. 2009;48:5007-17. doi:10.1021/bi900196c. PMID:19385636
   PubMed Web of Science ®Google Scholar
• Kumar A, Kamboj S, Malone BM, Kudo S, Twiss JL, Czymmek KJ, LaSalle JM, Schanen NC. Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo. J Cell Sci. 2008;121:1128-37. doi:10.1242/jcs.016865. PMID:18334558
   PubMed Web of Science ®Google Scholar
• Lever MA, Th'ng JP, Sun X, Hendzel MJ. Rapid exchange of histone H1.1 on chromatin in living human cells. Nature. 2000;408:873-6. doi:10.1038/35048603. PMID:11130728
   PubMed Web of Science ®Google Scholar
• Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, Chen WG, Lin Y, Savner E, Griffith EC, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron. 2006;52:255-69. doi:10.1016/j.neuron.2006.09.037. PMID:17046689
   PubMed Web of Science ®Google Scholar
• Stefanelli G, Gandaglia A, Costa M, Cheema MS, Di Marino D, Barbiero I, Kilstrup-Nielsen C, Ausio J, Landsberger N. Brain phosphorylation of MeCP2 at serine 164 is developmentally regulated and globally alters its chromatin association. Sci Rep. 2016;6:28295. doi:10.1038/srep28295. PMID:27323888
   PubMed Web of Science ®Google Scholar
• Bellini E, Pavesi G, Barbiero I, Bergo A, Chandola C, Nawaz MS, Rusconi L, Stefanelli G, Strollo M, Valente MM, et al. MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis? Front Cell Neurosci. 2014;8:236. doi:10.3389/fncel.2014.00236. PMID:25165434
   PubMed Web of Science ®Google Scholar
• Cohen S, Gabel HW, Hemberg M, Hutchinson AN, Sadacca LA, Ebert DH, Harmin DA, Greenberg RS, Verdine VK, Zhou Z, et al. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron. 2011;72:72-85. doi:10.1016/j.neuron.2011.08.022. PMID:21982370
   PubMed Web of Science ®Google Scholar
• Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302:885-9. doi:10.1126/science.1086446. PMID:14593183
   PubMed Web of Science ®Google Scholar
• Milton SG, Mathew OP, Yatsu FM, Ranganna K. Differential cellular and molecular effects of butyrate and trichostatin a on vascular smooth muscle cells. Pharmaceuticals (Basel). 2012;5:925-43. doi:10.3390/ph5090925. PMID:24280698
   PubMedGoogle Scholar
• Chao HT, Zoghbi HY. The yin and yang of MeCP2 phosphorylation. Proc Natl Acad Sci U S A. 2009;106:4577-8. doi:10.1073/pnas.0901518106. PMID:19293386
   PubMed Web of Science ®Google Scholar
• Tao J, Hu K, Chang Q, Wu H, Sherman NE, Martinowich K, Klose RJ, Schanen C, Jaenisch R, Wang W, et al. Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. Proc Natl Acad Sci U S A. 2009;106:4882-7. doi:10.1073/pnas.0811648106. PMID:19225110
   PubMed Web of Science ®Google Scholar
• Sekhavat A, Sun JM, Davie JR. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol. 2007;85:751-8. doi:10.1139/O07-145. PMID:18059533
   PubMed Web of Science ®Google Scholar
• Chao HT, Zoghbi HY. MeCP2: only 100% will do. Nat Neurosci. 2012;15:176-7. doi:10.1038/nn.3027. PMID:22281712
   PubMed Web of Science ®Google Scholar
• Nan X, Tate P, Li E, Bird A. DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol. 1996;16:414-21. doi:10.1128/MCB.16.1.414. PMID:8524323
   PubMed Web of Science ®Google Scholar
• Thambirajah AA, Ausio J. A moment's pause: putative nucleosome-based influences on MeCP2 regulation. Biochem Cell Biol. 2009;87:791-8. doi:10.1139/O09-054. PMID:19898528
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929-35. doi:10.1126/science.1132939. PMID:17008526
   PubMed Web of Science ®Google Scholar
• Yeakley JM, Shepard PJ, Goyena DE, VanSteenhouse HC, McComb JD, Seligmann BE. A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017;12:e0178302. doi:10.1371/journal.pone.0178302. PMID:28542535
   PubMed Web of Science ®Google Scholar
• Pandey P, Daghma DS, Houben A, Kumlehn J, Melzer M, Rutten T. Dynamics of post-translationally modified histones during barley pollen embryogenesis in the presence or absence of the epi-drug trichostatin A. Plant Reprod. 2017;30:95-105. doi:10.1007/s00497-017-0302-5. PMID:28526911
   PubMed Web of Science ®Google Scholar
• Sanders YY, Tollefsbol TO, Varisco BM, Hagood JS. Epigenetic regulation of thy-1 by histone deacetylase inhibitor in rat lung fibroblasts. Am J Respir Cell Mol Biol. 2011;45:16-23. doi:10.1165/rcmb.2010-0154OC. PMID:20724553
   PubMed Web of Science ®Google Scholar
• Raghuram N, Carrero G, Stasevich TJ, McNally JG, Th'ng J, Hendzel MJ. Core histone hyperacetylation impacts cooperative behavior and high-affinity binding of histone H1 to chromatin. Biochem. 2010;49:4420-31. doi:10.1021/bi100296z.
   PubMed Web of Science ®Google Scholar
• iClaveria-Gimeno R, Abian O, Velazquez-Campoy A, Ausió J. MeCP2…Nature's wonder protein or medicine's most feared one. Curr Genet Med Rep. 2016;4:180-94. doi:10.1007/s40142-016-0107-0.
   Google Scholar
• Ghosh RP, Horowitz-Scherer RA, Nikitina T, Shlyakhtenko LS, Woodcock CL. MeCP2 binds cooperatively to its substrate and competes with histone H1 for chromatin binding sites. Mol Cell Biol. 2010;30(19):4656-70. doi:10.1128/MCB.00379-10. PMID:20679481
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jurkowska R, Soeroes S, Rajavelu A, Dhayalan A, Bock I, Rathert P, Brandt O, Reinhardt R, Fischle W, et al. Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res. 2010;38:4246-53. doi:10.1093/nar/gkq147. PMID:20223770
   PubMed Web of Science ®Google Scholar
• Felle M, Hoffmeister H, Rothammer J, Fuchs A, Exler JH, Langst G. Nucleosomes protect DNA from DNA methylation in vivo and in vitro. Nucleic Acids Res. 2011;39(16):6956-69. doi:10.1093/nar/gkr263. PMID:21622955
   PubMed Web of Science ®Google Scholar
• Raghuram N, Carrero G, Th'ng J, Hendzel MJ. Molecular dynamics of histone H1. Biochem Cell Biol. 2009;87:189-206. doi:10.1139/O08-127. PMID:19234534
   PubMed Web of Science ®Google Scholar
• Ridsdale JA, Hendzel MJ, Delcuve GP, Davie JR. Histone acetylation alters the capacity of the H1 histones to condense transcriptionally active/competent chromatin. J Biol Chem. 1990;265:5150-6. PMID:2318888
   PubMed Web of Science ®Google Scholar
• Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003;302:890-3. doi:10.1126/science.1090842. PMID:14593184
   PubMed Web of Science ®Google Scholar
• Eickhoff B, Germeroth L, Stahl C, Kohler G, Ruller S, Schlaak M, van der Bosch J. Trichostatin A-mediated regulation of gene expression and protein kinase activities: reprogramming tumor cells for ribotoxic stress-induced apoptosis. Biol Chem. 2000;381:1127-32. doi:10.1515/BC.2000.138. PMID:11154071
   PubMed Web of Science ®Google Scholar
• Buchthal B, Lau D, Weiss U, Weislogel JM, Bading H. Nuclear calcium signaling controls methyl-CpG-binding protein 2 (MeCP2) phosphorylation on serine 421 following synaptic activity. J Biol Chem. 2012;287:30967-74. doi:10.1074/jbc.M112.382507. PMID:22822052
   PubMed Web of Science ®Google Scholar
• Bracaglia G, Conca B, Bergo A, Rusconi L, Zhou Z, Greenberg M, Landsberger N, Soddu S, Kilstrup-Nielsen C. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep. 2009;10:1327-33. doi:10.1038/embor.2009.217. PMID:19820693
   PubMed Web of Science ®Google Scholar
• Mari F, Azimonti S, Bertani I, Bolognese F, Colombo E, Caselli R, Scala E, Longo I, Grosso S, Pescucci C, et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet. 2005;14:1935-46. doi:10.1093/hmg/ddi198. PMID:15917271
   PubMed Web of Science ®Google Scholar
• Zhu YC, Li D, Wang L, Lu B, Zheng J, Zhao SL, Zeng R, Xiong ZQ. Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. Proc Natl Acad Sci US A. 2013;110:9118-23. doi:10.1073/pnas.1300003110.
   PubMed Web of Science ®Google Scholar
• Feng J, Nestler EJ. MeCP2 and drug addiction. Nat Neurosci. 2010;13:1039-41. doi:10.1038/nn0910-1039. PMID:20740030
   PubMed Web of Science ®Google Scholar
• Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, Attner MA, Cabrera SM, McDonough CB, Brindle PK, Abel T, et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci. 2007;27:6128-40. doi:10.1523/JNEUROSCI.0296-07.2007. PMID:17553985
   PubMed Web of Science ®Google Scholar
• Brown CR, Kennedy CJ, Delmar VA, Forbes DJ, Silver PA. Global histone acetylation induces functional genomic reorganization at mammalian nuclear pore complexes. Genes Dev. 2008;22:627-39. doi:10.1101/gad.1632708. PMID:18316479
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-5. doi:10.1038/227680a0. PMID:5432063
   PubMed Web of Science ®Google Scholar
• Stuss DP, Cheema M, Ng MK, Martinez de Paz A, Williamson B, Missiaen K, Cosman JD, McPhee D, Esteller M, Hendzel M, et al. Impaired in vivo binding of MeCP2 to chromatin in the absence of its DNA methyl-binding domain. Nucleic Acids Res. 2013;41:4888-900. doi:10.1093/nar/gkt213. PMID:23558747
   PubMed Web of Science ®Google Scholar
• Carrero G, McDonald D, Crawford E, de_Vries G, Hendzel MJ. Using FRAP and mathematical modeling to determine the in vivo kinetics of nuclear proteins. Methods (San Diego, Calif). 2003;29:14-28. doi:10.1016/S1046-2023(02)00288-8. PMID:12543068
   PubMed Web of Science ®Google Scholar
• Remenyi J, van den Bosch MW, Palygin O, Mistry RB, McKenzie C, Macdonald A, Hutvagner G, Arthur JS, Frenguelli BG, Pankratov Y. miR-132/212 knockout mice reveal roles for these miRNAs in regulating cortical synaptic transmission and plasticity. PLoS One. 2013;8:e62509. doi:10.1371/journal.pone.0062509. PMID:23658634
   PubMed Web of Science ®Google Scholar